Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Common Equity: 2013-2025

Historic Common Equity for Theravance Biopharma (TBPH) over the last 12 years, with Sep 2025 value amounting to $232.7 million.

  • Theravance Biopharma's Common Equity rose 25.33% to $232.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $232.7 million, marking a year-over-year increase of 25.33%. This contributed to the annual value of $175.5 million for FY2024, which is 17.58% down from last year.
  • According to the latest figures from Q3 2025, Theravance Biopharma's Common Equity is $232.7 million, which was up 3.48% from $224.8 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Common Equity registered a high of $480.6 million during Q3 2022, and its lowest value of -$373.2 million during Q1 2021.
  • For the 3-year period, Theravance Biopharma's Common Equity averaged around $226.6 million, with its median value being $213.0 million (2023).
  • Its Common Equity has fluctuated over the past 5 years, first plummeted by 136.31% in 2021, then surged by 248.51% in 2022.
  • Over the past 5 years, Theravance Biopharma's Common Equity (Quarterly) stood at -$338.6 million in 2021, then soared by 230.49% to $441.8 million in 2022, then crashed by 51.79% to $213.0 million in 2023, then decreased by 17.58% to $175.5 million in 2024, then rose by 25.33% to $232.7 million in 2025.
  • Its Common Equity was $232.7 million in Q3 2025, compared to $224.8 million in Q2 2025 and $166.0 million in Q1 2025.